CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC ...

Adding ivonescimab to chemotherapy prolonged progression-free survival (PFS) in previously treated advanced EGFR -mutant ...

A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary ...

Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer to evaluate coexisting splicing gene and pathway mutations: A CBioportal database analysis.

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in ...

With the approval, patients with EGFR exon 20 insertion mutations now have a once-a-day, oral option.

Pinetree will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique ...

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double ...